Apogee Therapeutics Inc’s recently made public that its Chief Medical Officer Dambkowski Carl unloaded Company’s shares for reported $0.14 million on Apr 02 ’25. In the deal valued at $36.22 per share,3,860 shares were sold. As a result of this transaction, Dambkowski Carl now holds 247,173 shares worth roughly $8.79 million.
Then, CARL DAMBKOWSKI bought 9,310 shares, generating $331,529 in total proceeds.
Before that, Dambkowski Carl sold 1,590 shares. Apogee Therapeutics Inc shares valued at $48,463 were divested by the Chief Medical Officer at a price of $30.48 per share. As a result of the transaction, Dambkowski Carl now holds 251,033 shares, worth roughly $8.93 million.
Citigroup initiated its Apogee Therapeutics Inc [APGE] rating to a Buy in a research note published on March 13, 2025; the price target was $95. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in late November with a ‘”a Buy”‘ rating. BofA Securities began covering APGE with “Buy” recommendation on May 10, 2024. BTIG Research started covering the stock on December 20, 2023. It rated APGE as “a Buy”.
Price Performance Review of APGE
On Tuesday, Apogee Therapeutics Inc [NASDAQ:APGE] saw its stock fall -9.70% to $35.57. Over the last five days, the stock has lost -5.85%. Apogee Therapeutics Inc shares have fallen nearly -21.48% since the year began. Nevertheless, the stocks have fallen -31.86% over the past one year. While a 52-week high of $63.50 was reached on 01/07/25, a 52-week low of $26.20 was recorded on 04/08/25. SMA at 50 days reached $35.94, while 200 days put it at $44.80.
Levels Of Support And Resistance For APGE Stock
The 24-hour chart illustrates a support level at 34.26, which if violated will result in even more drops to 32.95. On the upside, there is a resistance level at 38.07. A further resistance level may holdings at 40.57. The Relative Strength Index (RSI) on the 14-day chart is 47.34, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.72, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 56.67%. Stochastics %K at 72.24% indicates the stock is a holding.
The most recent change occurred on August 08, 2023 when Wedbush began covering the stock and recommended ‘”an Outperform”‘ rating along with a $40 price target.
